Arctic Blue Beverages Wins Big Again in San Francisco – “A Superior Result”
12.4.2022 19:00:00 EEST | Business Wire | Press release
Products of the Finnish beverage company Arctic Blue Beverages succeeded nobly at the prestigious The San Francisco World Spirit Competition (SFWSC). The company's newest gins, Arctic Blue Legacy Gin and Arctic Blue Gin Rose, won double gold. Silver was awarded to the innovative oat liqueur, Arctic Blue Oat.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005706/en/
“Although we know our products rank high in taste and quality globally, this was still an overwhelming result, for a relatively small player in the global alcohol industry,” Valtteri Eroma (left), the CEO of Arctic Blue Beverages, rejoices and adds: “Developing new products is always a team effort, but the key role in the taste of Arctic Blue products plays our internationally awarded Master Distiller Asko Ryynänen (right)." (Photo: Business Wire)
“Although we know our products rank high in taste and quality globally, this was still an overwhelming result, for a relatively small player in the global alcohol industry,” Valtteri Eroma, the CEO of Arctic Blue Beverages, rejoices.
“Developing new products is always a team effort, but the key role in the taste of Arctic Blue products plays our internationally awarded Master Distiller Asko Ryynänen. With Asko, we have developed an agile process to turn ideas effectively into award-winning products, which is now paying off,” Valtteri adds.
Arctic Blue Legacy is a barrel-aged gin sold in a unique bottle designed by Timo Sarpaneva. The product is targeted to the ultra-premium category and packed in a prestige handmade wooden gift package. It has already received the highest recognition at the International Wine and Spirit Competition (IWSC) with a gold medal and 95 points back in 2021.
Arctic Blue Gin Rose is the company's entry into the fast-growing category of pink gins. The taste profile is similar to the multi-award winning Arctic Blue Gin with hints of cinnamon rose petals in both scent and taste. The beautiful red color comes from Finnish bilberries.
Arctic Blue Oat is the world’s first gin-based oat liqueur, which was launched a year ago. It was already awarded with a bronze medal at the International Wine and Spirit Competition (IWSC) in 2021.
“Based on our experience after previous awards, this will give a great boost to the sales of our new products as well as our current products like Arctic Blue Oat. Therefore, immediately after hearing the preliminary information, we have worked hard to increase the production capacity of our products at the distillery,” says Valtteri Eroma.
Products of Arctic Blue Beverages have previously been successful in the SFWSC competition. For example in 2019 Arctic Blue Navy Strength Gin won Double Gold and the Best in Show awards at the World Spirits Awards in San Francisco.
Awards for Arctic Blue Beverages in 2022:
DOUBLE GOLD MEDAL, Arctic Blue Gin Rose (Flavoured Gin Category)
DOUBLE GOLD MEDAL, Arctic Blue Legacy Gin (Barrel Aged Gin Category)
SILVER MEDAL, Arctic Blue Oat, Finland (Other Liqueurs Category)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005706/en/
Contact information
Valtteri Eroma
CEO & Head of Brand
+358 40 550 1343
valtteri.eroma@arcticbluebeverages.com
Anniina Nissinen
PR- & communications Agency Mellakka Helsinki
+358 400 380010
anniina.nissinen@mellakka.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom